Senolytics: Clearing the Cells That Refuse to Die

Aging tissues accumulate senescent cells — cells that have stopped dividing but refuse to die, secreting inflammatory signals that damage neighboring tissue. FOXO4-DRI targets exactly that: it disrupts the FOXO4-p53 interaction that keeps senescent cells alive, freeing p53 to trigger apoptosis in them specifically.

The D-retro-inverso (DRI) modification is the engineering trick that makes it feasible. Built from D-amino acids in reversed sequence, a DRI peptide is protease-resistant — it persists where a normal peptide would be chopped apart in minutes. That stability is essential for disrupting an intracellular protein-protein interaction.

Senolytics is a frontier, and FOXO4-DRI is one of its most-discussed tools, but it's entirely preclinical. Members discuss it as a window into how the field is thinking about aging mechanistically — and the thread below is honest about how far the evidence is from human use.